Home page News Related Researches 2020-2029

Levels of Serum 25-Hydroxy Vitamin D in Benign and Malignant Breast Disease Patients: An Observational Study

Published on Thursday, 17 July 2025

Abstract

Introduction: Vitamin D deficiency is the foremost underdiagnosed and under-treated nutritional deficiency in the world. This vitamin deficiency has reached pandemic proportions despite being synthesized in the human body under sun exposure. Vitamin D plays a significant role in the maintenance of reproductive health and physiology in the human body. Its deficiency has been studied extensively in correlation with breast diseases and has been implicated as a risk factor for breast cancer by many. Thus, we undertook this study on patients with benign or malignant breast disease to assess the levels of vitamin D in the blood.

Methods: This prospective observational study was conducted at a tertiary care center in central India. All adult female patients who were admitted to the Department of Surgery with breast disease from January 2023 to June 2024 were included in the study. Exclusion criteria were women who had taken vitamin D supplementation in the previous two years, those with pre-existing vitamin D deficiency, or those who took therapy for osteopenia or osteoporosis. Patients finally included in the study were tested for serum vitamin D levels, estimated by the chemiluminescence method.

Results: Out of 85 patients with benign or malignant breast diseases, 37 (43.5%) patients had normal vitamin D levels, 34 (40.0%) had vitamin D insufficiency, and 14 (16.5 %) had vitamin D deficiency. Sixty-nine (81.17%) patients had benign breast disease and 16 (18.83%) had breast cancer. As compared with benign breast disease patients, those with malignant breast disease had significantly low serum 25-hydroxy vitamin D levels (p-value < 0.001).

Conclusion: The significant difference in mean 25-hydroxy vitamin D levels between benign breast disease and breast carcinoma patients favors the recommendation that vitamin D supplementation may eliminate a potential risk factor in breast cancer development, though larger sized studies and randomized trials are needed to establish a definite clinical correlation. While considering vitamin D supplementation, its non-skeletal effects should be taken into account more than the skeletal effects.

Download the complete article

About this publication.

The Di Bella's Method: Use of Vitamin D analogues and/or derivatives (together with others chemical compounds) in Breast Cancer:

- A retrospective observational clinical study of triple negative breast cancer cases treated with Di Bella Method: A preliminary data;

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- The Di Bella Method (A Fixed Part - Dihydrotachysterol, Alfacalcidol, synthetic Vitamin D3);

- Vitamin D (analogues and/or derivatives) and cancer - In vitro, review and in vivo publications;

The Di Bella's Method: Use of Vitamin D analogues and/or derivatives - together with others chemical compounds - in several Oncological Pathologies:

- A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Pleural Mesothelioma: clinical records on 11 patients treated with Di Bella's Method;

- Malignant pleural mesothelioma, stage T3-T4. Consideration of a case study;

- Excellent result in a Mesothelioma case treated exclusively with Di Bella Method for over 4 years and still treatment with positive results;

- A case of advanced Multiple Myeloma treated with Di Bella Method (DBM) into total remission for 13 years;

- Neuroblastoma: Complete objective response to biological treatment;